Biotest obtained US FDA Emergency Use Authorization

2020-06-05

    

RightSignTM COVID-19 IgG/IgM Rapid Test Cassette

 US FDA Emergency Use Authorized




 Dear Customer


We have good news about our COVID-19 serology test to share with you.


RightSignTM COVID-19 IgG/IgM Rapid Test Cassette from Hangzhou Biotest Biotech Co., Ltd was awarded  Emergency Use Authorization ("EUA") issued by the U.S. Food and Drug Administration (FDA) on June 4th, 2020. 


The relevant information is as follows:


         

RightSignTM COVID-19 IgG/IgM Rapid Test Cassette has obtained the Emergency Use Authorization (EUA) issued by the US FDA, and obtained the sales qualification in the US market, which will be conducive to the promotion and sales of the company's COVID-19 antibody test products in the US market, also will enhance the influence of Biotest and promote the sales of related products in other international regions.



Previous Page:Nothing
本网站由阿里云提供云计算及安全服务